Clinical Trials Browser

Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Clear all

NCT05658003 2026-03-23

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Phase 2 Active not recruiting

63 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05806814 2026-03-05

OU-SCC-EXCITE

Phase 1 Recruiting

13 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05670106 2026-02-13

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Phase 2 Active not recruiting

62 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Phase 1/2 Recruiting

39 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06134232 2025-08-27

ProvONE

Phase 2 Recruiting

400 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04015622 2025-08-20

PROTRACT

Phase 2 Active not recruiting

100 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

496 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03712930 2021-11-17

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Phase 2 Terminated

13 enrolled 11 charts

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03074032 2017-07-11

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Phase 1 Completed

17 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)